Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.
Price: $705.61, Change: $+19.25, Percent Change: +2.80%
What else is happening in Wire?
Wire
Cheesecake Factory Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours
Cheesecake Factory (CAKE) reported Q1 adjusted earnings late Wednesday of $1.05 per diluted share, up from $0.93 a year earlier.Analysts polled by FactSet expected $1.01.Revenue in the 13 weeks ended March 31 rose to $978.8 million from $927.2 million a year earlier.Analysts surveyed by FactSet expected $964.6 million.Cheesecake Factory shares rose 4.7% in after-hours trading.
$CAKE
Wire
Pilgrim's Pride Q1 Adjusted Earnings Fall, Sales Rise
Pilgrim's Pride (PPC) reported Q1 adjusted earnings late Wednesday of $0.51 per diluted share, down from $1.31 a year earlier.Analysts polled by FactSet expected $0.65.Net sales for the quarter ended March 29 rose to $4.53 billion from $4.46 billion a year earlier.Analysts surveyed by FactSet expected $4.43 billion.
$PPC
Wire
National Fuel Gas Fiscal Q2 Adjusted Earnings, Revenue Rise
National Fuel Gas (NFG) reported fiscal Q2 adjusted earnings late Wednesday of $2.71 per diluted share, up from $2.39 a year earlier.Analysts polled by FactSet expected $2.84.Revenue for the three months ended March 31 was $858.4 million, up from $730 million a year earlier.Analysts surveyed by FactSet expected $856.6 million.The company revised its fiscal 2026 adjusted EPS guidance range to $7.45 to $7.75 from $7.60 to $8.10 earlier. Analysts expect $7.79.
$NFG